Business Description
Chemomab Therapeutics Ltd
ISIN : US16385C2035
Share Class Description:
CMMB: ADRTotal Employee Number:
12Description
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 47 | |||||
3-Year EPS without NRI Growth Rate | 47 | |||||
3-Year FCF Growth Rate | 37.6 | |||||
3-Year Book Growth Rate | -49.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.86 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.5 | |||||
9-Day RSI | 33.68 | |||||
14-Day RSI | 38.92 | |||||
3-1 Month Momentum % | -3.73 | |||||
6-1 Month Momentum % | -7.74 | |||||
12-1 Month Momentum % | -64.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.31 | |||||
Quick Ratio | 10.31 | |||||
Cash Ratio | 7.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -68.49 | |||||
ROA % | -60.1 | |||||
ROIC % | -409.69 | |||||
3-Year ROIIC % | -4773.76 | |||||
ROC (Joel Greenblatt) % | -1512.78 | |||||
ROCE % | -72.71 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.92 | |||||
Price-to-Tangible-Book | 0.92 | |||||
EV-to-EBIT | 0.04 | |||||
EV-to-EBITDA | 0.04 | |||||
EV-to-FCF | 0.03 | |||||
| Price-to-Net-Current-Asset-Value | 0.95 | |||||
| Price-to-Net-Cash | 1.43 | |||||
Earnings Yield (Greenblatt) % | 2500 | |||||
FCF Yield % | -110.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CMMB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chemomab Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.12 | ||
| Beta | 1.8832 | ||
| 3-Year Sharpe Ratio | -0.14 | ||
| 3-Year Sortino Ratio | -0.23 | ||
| Volatility % | 72.14 | ||
| 14-Day RSI | 38.92 | ||
| 14-Day ATR ($) | 0.184372 | ||
| 20-Day SMA ($) | 1.723 | ||
| 12-1 Month Momentum % | -64.45 | ||
| 52-Week Range ($) | 1.35 - 4.8 | ||
| Shares Outstanding (Mil) | 7.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chemomab Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chemomab Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 19 days | ||
| Chemomab Therapeutics and Scipher Medicine Merger Announcement Conference Call | 2026-07-08 08:15 | 2.77 (+15.42%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.74 (-5.95%) | ||
| General meeting for 2026 | 2026-05-05 16:30 | 1.62 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 1.78 (-6.32%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 2.00 (-2.07%) | ||
| Oppenheimer 36(th) Annual Healthcare Life Sciences Conference | 2026-02-26 08:00 | 1.44 (-5.33%) | ||
| Third quarter earnings results for 2025 | 2025-11-20 | 2.70 (-3.91%) | ||
| Guidance call for 2025 | 2025-09-05 07:00 | 3.05 (+1.33%) |
Show
Entries
Chemomab Therapeutics Ltd Frequently Asked Questions
What is Chemomab Therapeutics Ltd(CMMB)'s stock price today?
The current price of CMMB is $1.37. The 52 week high of CMMB is $4.80 and 52 week low is $1.35.
When is next earnings date of Chemomab Therapeutics Ltd(CMMB)?
The next earnings date of Chemomab Therapeutics Ltd(CMMB) is 2026-08-14 Est..
Does Chemomab Therapeutics Ltd(CMMB) pay dividends? If so, how much?
Chemomab Therapeutics Ltd(CMMB) does not pay dividend.
Guru Commentaries on NAS:CMMB
No articles.
Press Release
Articles on Chemomab Therapeutics Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers